Pharmacological treatment of obesity

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 2, 2006, Pages 377-389

  Mancini, Marcio C ^a,b   Halpern, Alfredo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Anfepramone; Mazindol; Obesity; Orlistat; Rimonabant; Sibutramine; Treatment

Indexed keywords

AMPHETAMINE DERIVATIVE; ANFEPRAMONE; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE; LACTONE; MAZINDOL; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); DRUG EFFECT; ENERGY METABOLISM; HOMEOSTASIS; HUMAN; OBESITY; REVIEW; WEIGHT REDUCTION;

AMPHETAMINES; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; CYCLOBUTANES; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; LACTONES; MAZINDOL; OBESITY; PIPERIDINES; PYRAZOLES; WEIGHT LOSS;

EID: 33744500755     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302006000200024     Document Type: Review

References (95)

1. WHO Consultation on Obesity. Preventing and managing the global epidemic. Geneva: World Health Organization, 1998.
2. Guy-Grand B. Long-term pharmacoterapy in the management of obesity. In: Björntorp P, Rössner S, editors. From theory to practice: Obesity in Europe - 88. London: John Libbey, 1989. p.311-8.
3. Gortmaker SL, Must A, Perrin JM, Sobol AM, Dietz WH. Social and economic consequences of overweight in adolescence and young adulthood. N Engl J Med 1993;329:1008-12.
4. Bray GA. Obesity - a time bomb to be refused. Lancet 1998;352:160-1.
5. Prentice AM, Jebb AS. Obesity in Britain: gluttony or sloth? Br Med J 1995;311:437-9.
6. Halpern A, Mancini MC. Treatment of obesity: an update on anti-obesity medications. Obes Rev 2003;4:25-42.
7. Williamson DF. Dietary intake and physical activity as "predictors" of weight gain in observational, prospective studies. Nutr Rev 1996;54(suppl):S101-9.
8. Samanin R, Garattini S. Neurochemical mechanism of action of anorectic drugs. Pharmacol Toxicol 1993;73:63-8.
9. Garattini S. Biological actions of drugs affecting serotonin and eating. Obes Res 1995;3:463-70.
10. Heal DJ, Frankland AT, Gosden J, Hutchins LJ, Prow MR, Luscombe GP, et al. A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine. Psychopharmacology 1992;107:303-9.
11. Paul SM, Hulihan-Giblin B, Skolnick P. (+)-Amphetamine binding to rat hypothalamus: relation to anorexic potency of phenethylamines. Science 1982;218:487-90.
12. Angel I, Hauger RL, Luu MD, Giblin B, Skolnick P, Paul SM. Glucostatic regulation of (+)-[3H]amphetamine binding in the hypothalamus: correlation with Na+/K+-ATPase activity. Proc Natl Acad Sci USA 1985;82:6320-4.
13. Harris SC, Ivy AC, Searle LM. The mechanism of amphetamine-induced loss of weight. JAMA 1947;134:1468-75.
14. Petrie JC, Bewsher PD, Mowat JA, Stowers JM. Metabolic effects of fenfluramine - a double-blind study. Postgrad Med J 1975;51:139-44.
15. Blundell JE, Hill AJ. Serotoninergic drug potentates the satiating capacity of food - action of [scap]d-fenfluramine in obese subjects. Ann NY Acad Sci 1989;575:493-5.
16. Smith BK, York DA, Bray GA. Activation of hypothalamic serotonin receptors reduced intake of dietary fat and protein but not carbohydrate. Am J Physiol 1999;277:R802-11.
17. Foltin RW, Kelly TH, Fischman MW. Effect of amphetamine on human macronutrient intake. Physiol Behav 1995;58:899-907.
18. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord 1997;21(suppl):S25-9.
19. Cheymol G, Weissenburger J, Poirier JM, Gellee C. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. Br J Clin Pharmacol 1995;39:684-7.
20. Hinsvark ON, Truant AP, Jenden DJ, Steinborn JA. The oral bioavailability and pharmacokinetics of soluble and resin-bound forms of amphetamine and phentermine in man. J Pharmacokinet Biopharm 1973;1:319-28.
21. Coutts RT, Nazarali AJ, Baker GB, Pasutto FM. Metabolism and disposition of N-(2-cyanoethyl) amphetamine (fenproporex) and amphetamine: study in the rat brain. Can J Physiol Pharmacol 1986;64:724-8.
22. Mattei R, Carlini EA. A comparative study of the anorectic and behavioral effects of fenproporex on male and female rats. Braz J Med Biol Res 1996;29:1025-30.
23. Musshoff E. Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine. Drug Metab Rev 2000;32:15-44.
24. Silverstone PH, Oldman D, Johnson B, Cowen PJ. Ondansetron, a 5-HT3 receptor antagonist, partially attenuates the effects of amphetamine: a pilot study in healthy volunteers. Int Clin Psychopharmacol 1992;7:37-43.
25. Wurtman JJ. Carbohydrate craving. Relationship between carbohydrate intake and disorders of mood. Drugs 1990;39:49-52.
26. Goodall EM, Feeney S, McGuirk J, Silverstone T. A comparison of the effects of d- and l-fenfluramine and damphetamine on energy and macronutrient intake in human subjects. Psychopharmacology 1992;106:221-7.
27. Lafreniere F, Lambert J, Rasio E, Serri O. Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study. Int J Obes Relat Metab Disord 1993;17:25-30.
28. Goodall EM, Cowen PJ, Franklin M, Silverstone T. Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers. Psychopharmacology (Berl) 1993;112:461-6.
29. Cowen PJ, Sargent PA, Williams C, Goodall EM, Orlikov AB. Hypophagic, endocrine and subjective responses to m-chlorophenylpiperazine in healthy men and women. Hum Psychopharmacol 1995;10:385-91.
30. Boeles S, Williams C, Campling GM, Goodall EM, Cowen PJ. Sumatriptan decreases food intake and increases plasma growth hormone in healthy women. Psychopharmacology (Berl) 1997;129:179-82.
31. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981;304:930-3.
32. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999;7:189-98.
33. Stevens VJ, Obarzanek E, Cook NR, Lee I-M, et al; the Trials of Hypertension Prevention Research Group. Long-term weight loss and changes in blood pressure: results of the trials of hypertension prevention, phase II. Ann Intern Med 2001;134:1-11.
34. Mikhail N, Golub MS, Tuck ML. Obesity and hypertension. Prog Cardiovasc Dis 1999;42:39-58.
35. Noble RE. A six-month study of the effects of dexfenfluramine on partially successful dieters. Curr Ther Res 1990;47:612-9.
36. Kolanowski J, Younis LT, Vanbutsele R, Detry JM. Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients. Eur J Clin Pharmacol 1992;42:599-606.
37. Fletchner Mors M, Ditschuneit HH, Yip I, Adler G. Blood pressure and plasma norepinephrine responses to dexfenfluramine in obese postmenopausal women. Am J Clin Nutr 1998;67:611-5.
38. Goldstein DJ. Beneficial health effects of modest weight-loss. Int J Obes Relat Metab Disord 1992;16:397-415.
39. Sjöström CD, Lissner L, Wedel H, Sjöström L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS intervention study. Obes Res 1999;7:477-84.
40. Turtle JR, Burgess JA. Hypoglycemic action of fenfluramine in diabetes mellitus. Diabetes 1973;22:858-67.
41. Andersen PH, Richelsen B, Bak J, Schmitz O, Sorensen NS, Lavielle R, et al. Influence of short-term dexfenfluramine therapy on glucose and lipid metabolism in obese nondiabetic patients. Acta Endocrinol (Copenh) 1993;128:251-8.
42. Marks SJ, Moore NR, Clarck ML, Strauss BJ, Hockaday TD. Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM. Int J Obes Relat Metab Disord 1997;21:274-9.
43. Feeney S, Goodall E, Silverstone T. The prolactin response to d- and l-fenfluramine and to d-amphetamine in human subjects. Int Clin Psychopharmacol 1993;8:49-54.
44. Shapira B, Cohen J, Newman ME, Lerer B. Prolactin response to fenfluramine and placebo challenge following maintenance pharmacoterapy withdrawal in remitted depressed patients. Biol Psychiatry 1993;33:531-5.
45. Boushaki FZ, Rasio E, Serri O. Hypothalamic-pituitary-adrenal axis in abdominal obesity: effects of dexfenfluramine. Clin Endocrinol (Oxf) 1997;46:461-6.
46. Medeiros-Neto G, Lima N, Perozim L, Pedrinola F, Wajchenberg BL. The effect of hypocaloric diet with and without D-fenfluramine treatment on growth hormone release after growth hormone-releasing factor stimulation in patients with android obesity. Metabolism 1994;43:969-73.
47. Kars ME, Pijl H, Cohen AF, Frolich M, Schoemaker HC, Brandenburg HC, et al. Specific stimulation of brain serotonin mediated neurotransmission by dexfenfluramine does not restore growth hormone responsiveness in obese women. Clin Endocrinol (Oxf) 1996;44:541-6.
48. Jonderko K, Kucio C. Extra-anorectic actions of mazindol. Isr J Med Sci 1989;25:20-4.
49. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000;2:105-12.
50. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, et al; Sibutramine/Diabetes Clinical Study Group. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000;2:175-87.
51. Levitsky DA, Schuster JA, Stallone D, Strupp BJ. Modulation of the thermic effect of food by fenfluramine. Int J Obes 1986;10:169-73.
52. Scalfi L, D'Arrigo E, Carandente V, Coltorti A, Contaldo F. The acute effect of fexfenfluramine on resting metabolic rate and postprandial thermogenesis in obese subjects: a double-blind placebo-controlled study. Int J Obes Relat Metab Disord 1993;17:91-6.
53. Van Gaal LF, Vansant GA, Steijaert MC, De Leeuw IH. Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction. Metabolism 1995;44:42-5.
54. Breum L, Astrup A, Andersen T, Lambert O, Nielsen E, Garby L, et al. The effect of long-term dexfenfluramine treatment on 24-hour energy-expenditure in man - a double-blind placebo controlled study. Int J Obes Relat Metab Disord 1990;14:613-21.
55. Seagle HM, Bessesen DH, Hill JO. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res 1998;6:115-21.
56. Hansen DL, Toubro S, Stock MJ, MacDonald IA, Astrup A. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998;68:1180-6.
57. Alger S, Larson K, Boyce VL, Seagle H, Fontvieille AM, Ferraro RT, et al. Effect of phenylpropanolamine on energy expenditure and weight loss in overweight women. Am J Clin Nutr 1993;57:120-6.
58. Rascovski A, Millner TH, Batalha L, Reis C, Mancini MC, Halpern A. Eficácia e tolerabilidade das substâncias calorigênicas: ioimbina, triiodotironina, aminofilina combinada a efedrina e fenilpropanolamina no tratamento da obesidade a curto prazo. Arq Bras Endocrinol Metab 2000;44:95-102.
59. Liu YL, Toubro S, Astrup A, Stock MJ. Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int J Obes Relat Metab Disord 1995;19:678-85.
60. Pasquali R, Cesari MP, Melchionda N, Stefanini C, Raitano A, Labo G. Does ephedrine promote weight loss in low-energy adapted obese women? Int J Obes 1987;11:163-8.
61. Halpern A, Mancini MC. Tratamento farmacológico da obesidade - Drogas termogênicas. Arq Bras Endocrinol Metab 1996;40:224-7.
62. Dulloo AG, Seydoux J, Girardier L. Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxantines: adenosine antagonism or phosphodiesterase inhibition. Metabolism 1992;41:1233-41.
63. Astrup A, Toubro S, Cannon S, Hein P, Madsen J. Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study. Metabolism 1991;40:323-9.
64. Mancini MC, Marsiaj HI, Hakoyama MM, Quantal IA, Correa NC, Halpern A. Ephedrine, caffeine and aminophilline preparation: na alternative in the treatment of obesity. Int J Obes 1990;14(suppl 2):141.
65. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8.
66. Graham DJ, Green L. Further cases of valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:635.
67. Leite CC, Mancini MC, Medeiros CCJ, Sbano JCN, Grinberg M, Halpern A. Echocardiographic evaluation of 70 patients using dexfenfluramine (abstracted). Int J Obes Relat Metab Disord 1998;22(suppl 3):S227.
68. Weissman NJ, Tighe JF, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med 1998;339:725-32.
69. Abenhaim L, Moride Y, Brenot F, et al. Appetite-supressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-16.
70. Hagiwara M, Tsuchida A, Hyakkoku M, et al. Delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol: a case report. Jpn Circ 2000;64:218-21.
71. Thomas SH, Butt AY, Corris PA, et al. Appetite supressants and primary pulmonary hypertension in the United Kingdom. Br Heart J 1995;74:660-3.
72. Little JD, Romans SE. Psychosis following readministration of diethylpropion: a possible role for kinding? Int Clin Psychopharmacol 1993;8:67-70.
73. Luque CA, Ray JA. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother 1999;33:968-78.
74. McMahon FG, Fujioka K, Singh BN, Mendel CM, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled multicenter trial. Arch Int Med 2000;160:2185-91.
75. Horwitz RI, Brass LM, Kernan WN, Viscoli CM. Phenylpropanolamine and risk of hemorrhagic stroke: final report of the hemorrhagic stroke project. http://fda.gov/ohrms/dockets/ac/00/backgrd/3647b1_tab19.doc (accessed on March 2, 2001).
76. Neilsen JA, Chapin DS, Johnson Jr JL, Torgersen LK. Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice. Am J Clin Nutr 1992;55(suppl):185S-9S.
77. McGuirk J, Silverstone T. The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. Int J Obes Relat Metab Disord 1990;14:361-72.
78. Gray DS, Fujioka K, Devine W, Bray GA. A randomized double-blind clinical trial of fluoxetine in obese diabetics. Int J Obes Relat Metab Disord 1992;16(suppl 4):S67-S72.
79. Wadden TA, Bartlett SJ, Foster GD, Greenstein RA, Wingate BJ, Stunkard AJ, et al. Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial. Obes Res 1995;3:549-57.
80. Ricca V, Mannucci E, Di Bernardo M, Rizzello SM, Cabras PL, Rotella CM. Sertraline enhances the effects of cognitive-behavioral treatment on weight reduction of obese patients. J Endocrinol Invest 1996;19:727-33.
81. Arterburn D, Noël PH. Extracts from "clinical evidence" - Obesity. Br Med J 2001;322:1406-9.
82. Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995;35:1103-8.
83. Aronne LJ. Modern medical management of obesity: the role for pharmacological intervention. J Am Diet Assoc 1998;98(suppl 2):S23-6.
84. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999;281:235-42.
85. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 1998;16:2013-7.
86. Sjöstrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-72.
87. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998;21:1288-94.
88. Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, et al. Latin-american trial of orlistat for weight loss and improvement in glycemic profile in obese diabetic patients. Diabetes Obes Metab 2003;5:180-8.
89. Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes 1993;17:241-4.
90. Drent ML, Larsson I, William-Olsson T, Quaade F, et al. Orlistat, a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes 1995;19:221-6.
91. Van Gaal LF, Bloom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month-dose-ranging study. Eur J Pharmacol 1998;54:125-32.
92. Daniels S. Pharmacological treatment of obesity in paediatric patients. Paediatr Drugs 2001;3:405-10.
93. Halpern A, Mancini MC. Diabesity: are weight loss medications effective? Treat Endocrinol 2005;4:65-74.
94. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61. Erratum in: Diabetes Care 2004;27:856.
95. van Gaal L, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.